Assessing predictive probability of success for future clinical trials.

IF 1.2 4区 医学 Q4 PHARMACOLOGY & PHARMACY
Archie Sachdeva, Ram Tiwari, Ming Zhou
{"title":"Assessing predictive probability of success for future clinical trials.","authors":"Archie Sachdeva, Ram Tiwari, Ming Zhou","doi":"10.1080/10543406.2025.2510262","DOIUrl":null,"url":null,"abstract":"<p><p>Data-driven decision-making is crucial in drug development, with the predictive probability of success (PoS) being a key quantitative tool. PoS estimates the likelihood of success of a future trial based on the same or surrogate endpoint(s) of interest, utilizing information from interim analyses, or completed historical studies. While it has been extensively studied and broadly applied in clinical practice, there is a growing need of a unified approach for PoS that can effectively incorporate information from surrogate endpoints and multiple historical studies. This paper investigates and assesses a unified Bayesian approach for PoS. We first review PoS based on historical data on the same endpoint and then extend it to include information from a surrogate endpoint with a closed-form solution. Additionally, we utilize a Bayesian meta-analytic approach to incorporate data from multiple historical studies. We illustrate the unified approach with examples from oncology and immunology trials and provide an R package \"PPoS\" for practical implementation. By integrating the assessment of PoS with information from surrogate endpoints and historical studies, we aim to enhance the decision-making process in drug development.</p>","PeriodicalId":54870,"journal":{"name":"Journal of Biopharmaceutical Statistics","volume":" ","pages":"1-23"},"PeriodicalIF":1.2000,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Biopharmaceutical Statistics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10543406.2025.2510262","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Data-driven decision-making is crucial in drug development, with the predictive probability of success (PoS) being a key quantitative tool. PoS estimates the likelihood of success of a future trial based on the same or surrogate endpoint(s) of interest, utilizing information from interim analyses, or completed historical studies. While it has been extensively studied and broadly applied in clinical practice, there is a growing need of a unified approach for PoS that can effectively incorporate information from surrogate endpoints and multiple historical studies. This paper investigates and assesses a unified Bayesian approach for PoS. We first review PoS based on historical data on the same endpoint and then extend it to include information from a surrogate endpoint with a closed-form solution. Additionally, we utilize a Bayesian meta-analytic approach to incorporate data from multiple historical studies. We illustrate the unified approach with examples from oncology and immunology trials and provide an R package "PPoS" for practical implementation. By integrating the assessment of PoS with information from surrogate endpoints and historical studies, we aim to enhance the decision-making process in drug development.

评估未来临床试验成功的预测概率。
数据驱动的决策在药物开发中至关重要,预测成功概率(PoS)是一个关键的定量工具。PoS是基于相同或替代终点,利用中期分析或已完成的历史研究的信息,估计未来试验成功的可能性。虽然它已被广泛研究并广泛应用于临床实践,但越来越需要一种统一的PoS方法,可以有效地整合来自替代终点和多个历史研究的信息。本文研究并评估了PoS的统一贝叶斯方法。我们首先基于同一端点上的历史数据审查PoS,然后将其扩展到包含代理端点的信息,并使用封闭形式的解决方案。此外,我们利用贝叶斯元分析方法来整合来自多个历史研究的数据。我们用肿瘤学和免疫学试验的例子说明了统一的方法,并提供了一个R包“PPoS”用于实际实施。通过将PoS评估与替代终点和历史研究的信息相结合,我们的目标是提高药物开发的决策过程。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Biopharmaceutical Statistics
Journal of Biopharmaceutical Statistics 医学-统计学与概率论
CiteScore
2.50
自引率
18.20%
发文量
71
审稿时长
6-12 weeks
期刊介绍: The Journal of Biopharmaceutical Statistics, a rapid publication journal, discusses quality applications of statistics in biopharmaceutical research and development. Now publishing six times per year, it includes expositions of statistical methodology with immediate applicability to biopharmaceutical research in the form of full-length and short manuscripts, review articles, selected/invited conference papers, short articles, and letters to the editor. Addressing timely and provocative topics important to the biostatistical profession, the journal covers: Drug, device, and biological research and development; Drug screening and drug design; Assessment of pharmacological activity; Pharmaceutical formulation and scale-up; Preclinical safety assessment; Bioavailability, bioequivalence, and pharmacokinetics; Phase, I, II, and III clinical development including complex innovative designs; Premarket approval assessment of clinical safety; Postmarketing surveillance; Big data and artificial intelligence and applications.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信